Race, APOE genotypes, and cognitive decline among middle-aged urban adults

Author/Creator ORCID

Date

2021-06-30

Department

Program

Citation of Original Publication

Beydoun, May A. et al.; Race, APOE genotypes, and cognitive decline among middle-aged urban adults; Alzheimer's Research & Therapy volume 13, Article number: 120, 30 June 2021; https://doi.org/10.1186/s13195-021-00855-y

Rights

This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
Public Domain Mark 1.0
This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.

Subjects

Abstract

Background Associations of Apolipoprotein (APOE) ε₂ or ε₄ (APOE₂ or APOE₄) dosages with cognitive change may differ across racial groups. Methods Longitudinal data on 1770 middle-aged White and African American adults was compiled from the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS 2004-2013) study. APOE₂ and APOE₄ dosages were the two main exposures, while v₁ and annual rate of change in cognitive performance (between v₁ and v₂) on 11 test scores were the main outcomes of interest (v1: 2004–2009 and v2: 2009–2013). Mixed-effects linear regression models were conducted adjusting for socio-demographic, lifestyle, and health-related potential confounders. Race (African American vs. White) and sex within racial groups were main effect modifiers. Results Upon adjustment for multiple testing and potential confounders, APOE₄ allelic dosage was associated with faster decline on a test of verbal memory among Whites only (CVLT-List A: γ₁₂ = − 0.363 ± 0.137, p = 0.008), but not among African Americans. In contrast, among African American women, APOE₄ dosage was linked to slower decline on a test of attention (BTA: γ₁₂ = + 0.106 ± 0.035, p = 0.002), while no association was detected among African American men. APOE₂ and APOE₄ dosages showed inconsistent results in other domains of cognition overall and across racial groups that did not survive correction for multiple testing. Conclusions In conclusion, APOE₄ dosage was associated with faster decline on a test of verbal memory among Whites only, while exhibiting a potential protective effect among African American women in the domain of attention. Further longitudinal studies are needed to replicate our race and sex-specific findings.